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S350 Poster Session IIto collect while no patient (0%) without previous LEN exposure
failed to collect, including 3 pts who received melphalan (p 5
0.105). Total number of CD34+ cells collected after 2 apheresis ses-
sions for group B 5 8.13x106/kg CD34+ cells and group A 5
3.34x106/kg CD34+ cells (p 5 0.06).
Conclusion: Chemomobilization with CTX + filgrastim yields ro-
bust PBSC collections irrespective of antecedent lenalidomide.
There was a trend towards lesser PBSC collection in LEN-treated
pts. Due to retrospective design and limited number of pts, further
research is needed to elucidate the effect of chemomobilization on
PBSC collection in LEN-treated pts.548
ADDITION OF RITUXIMAB TO EITHER BEAC OR BEAM IN THE PREPARA-
TIVE REGIMEN PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION
IN PATIENTSWITH RELAPSED B-CELL NON-HODGKIN LYMPHOMA DOES
NOT ADD A SURVIVAL BENEFIT: A SINGLE CENTER EXPERIENCE
Williams, C.B., Loknath-Kumar, A., Divine, C.L., Aljitawi, O.A.,
Abhyankar, S., McGuirk, J.P., Ganguly, S. University of Kansas Medical
Center, Kansas City, KS
High-dose chemotherapy with carmustine, etoposide, cytosine
arabinoside, and melphalan (BEAM) or cyclophosphamide
(BEAC) followed by autologous hematopoietic stem cell
transplantation (ASCT) represents a standard therapy for many
patients with relapsed non-Hodgkin lymphoma (NHL). Whether
or not the addition of rituximab to either preparative regimen
(R-BEAM or R-BEAC) provides a benefit when given prior to
ASCT is unclear.
In an attempt to compare the efficacy, outcome, and toxicity of
BEAM (with or without rituximab) (n 5 36) and BEAC (with or
without rituximab) (n 5 21) in patients with NHL undergoing
ASCT, we retrospectively evaluated our center’s experience between
January 2007 and April 2010.
Out of 57 patients with relapsedNHL (median age 56 y; range 25-
72 y), 13 patients received BEAM (n 5 6) or BEAC (n 5 7) and 44
patients received R-BEAM (n 5 29) or R-BEAC (n 5 15) prior to
ASCT. All patients received rituximab containing salvage chemo-
therapy prior to transplantation.
The probability of disease-free survival (DFS) (80% in BEAM/
BEAC versus 70% in R-BEAM/R-BEAC group; p 5 0.69) and
overall survival (OS) (68% in BEAM/BEAC versus 80% in R-
BEAM/R-BEAC group; p 5 0.31) were comparable in both the
groups at 2 years. The probability of DFS (100% in BEAC ver-
sus 70% in R-BEAC group; p 5 0.55; and 71% in BEAM and
69% in R-BEAM group; p 5 0.47) and OS (100% in BEAC ver-
sus 92% in R-BEAC group; p 5 0.54; and 60% in BEAM and
80% in R-BEAM group; p 5 0.22) were also comparable at 2
years.
There was no difference in engraftment kinetics, grade III-IV tox-
icities, and average length of stay among the different groups.
In conclusion, the addition of rituximab to either preparative reg-
imen did not add any benefit to our patients undergoing ASCT for
B-cell NHL. It is possible that the universal use of rituximab with
prior salvage therapies might have abrogated the benefit of R-
BEAM/R-BEAC over BEAM/BEAC in this study. Whether or not
the addition of rituximab to the preparative regimens prior to
ASCT in patients with NHL truly adds any benefit needs to be stud-
ied in a larger prospective trial.549
APREPITANT: TREATMENT IN HAEMATOPOIETIC STEM CELL TRANS-
PLANTATION (HSCT) PATIENTS REFRACTORY TO FIRST AND SECOND
LINE ANTIEMETICS
Booth, D. Alfred Hospital, Melbourne, Victoria, Australia
Chemotherapy induced nausea and vomiting (CINV) is a distressing
side effect of the transplant procedure.Evidencebasedguidelines exist to
direct antiemetic prescribing for the prevention ofCINV.There ismin-
imal research providing guidance in the management patients with de-
layed emesis despite appropriate preventative strategies for CINV,
particularly afterHSCT. Aprepitant is a neurokinin-1 antagonist, which
incombinationwith5HT3antagonists anddexamethasone is effective inpreventingacuteanddelayedemesis afterhighlyemetogenicchemother-
apy. Aprepitant has been utilised in HSCT for prevention of CINV.
Aim:To assess the efficacy of aprepitant for the treatment of refrac-
tory emesis following HSCT.
Methods: Patients transplanted between Sept 2008 to Aug 2009,
experiencing more than one emetic episode or persistent nausea
score . 5/10 for more than 24 hours after review of antiemetic
therapy were included. Aprepitant was administered in addition
to current antiemetic therapy, as either 115mg IV daily or
125mg po stat and then 80 mg daily. The number of vomiting ep-
isodes, dry retches, nausea score on a ten point scale and break-
through antiemetic use was recorded at baseline and daily until
aprepitant ceased. A complete response was defined as no emetic
episodes, nausea score of 0/10 and no breakthrough antiemetic
use. Major response was defined as no emetic episodes with reduc-
tion of nausea score from baseline of at least 50% and partial
response as no emetic episodes but reduction in nausea score of
\ 50%.
Results: During the audit period 14 patients were prescribed apre-
pitant to treat emesis. A complete response was seen in 4/14
(28%), major response in 2/14 (14%) and partial response in 4/14
(28%) with an overall repose rate of 10/14 (71%). Responses were
sustained.
Conclusion: The addition of aprepitant can prevent emesis and
reduce nausea score in HSCT patients refractory to first and second
line antiemetic therapy.550
WHAT GOES UP MUST COME DOWN: VORICONAZOLE AND CYCLO-
SPORIN IN A PAEDIATRIC CORD AND MARROW TRANSPLANT UNIT
Wright, F.A.1,2, Daly, G.E.1,2, Song, E.Y.3,4, O’Brien, T.A.1,3,4 1Sydney
Children’s Hospital, Randwick, NSW, Australia; 2Sydney Children’s Hos-
pital, Randwick, NSW, Australia; 3Sydney Cord and Marrow Transplant
Program, Randwick, NSW, Australia; 4University of New South Wales,
Randwick, NSW, Australia
Voriconazole’s addition to the antifungal armamentarium has
been revolutionary. Its use in invasive fungal infection is of particular
utility in haematopoietic stem cell transplant (HSCT). Voriconazole
inhibits hepatic enzymes placing HSCT patients at risk of drug in-
teractions and toxicity from calcineurin inhibitors. Limited safety
and efficacy data exist for pediatric HSCT warranting investigation.
Objective: To investigate the safety and efficacy of voriconazole in
a pediatric HSCT unit 2008-10.
Method: A retrospective chart review of 43 consecutive allogeneic
transplants identified patients who received voriconazole from con-
ditioning until Day 100.
Results: 39 out of 43 (90.7%) patients are alive with a median follow
up of 17 months (1-32). There were no deaths from fungal infection.
42 of 43 patients received fungal prophylaxis. 35 patients were clas-
sified as low risk of infection and received fluconazole. 7 patients
were high risk due to pre transplant infection and received voricona-
zole. 1 patient on voriconazole developed mucormycosis and was ef-
fectively treated with posaconazole. 2 patients had suspected fungal
disease and had treatment with another agent. 4 patients continued
on prophylaxis with no demonstration of fungal disease. 13 of 43
(30.2%) fluconazole prophylaxis patients changed to voriconazole
treatment for suspected fungal infection with symptom resolution
in all patients.
Voriconazole was well tolerated. 1 patient withdrew due to toxic-
ity (confusion, rash). Hepatic dysfunction (GGT 2x normal) was sig-
nificantly higher in the voriconazole group (p\0.01). There was no
difference in transaminitis across the two groups.
On voriconazole initiation, cyclosporin dose was modified on
a risk adjusted basis. Cyclosporin level, creatinine, nephrotoxic
agents and GVHD were used to inform decision. There was no dif-
ference in cyclosporin levels or renal impairment (2 x baseline CR
urea) in the voriconazole group compared to those who received
other agents.
Conclusion: Safety and efficacy data are limited for new antifungals
when used with standard medications in pediatric HSCT. This small
series demonstrated voriconazole has acceptable toxicity and can be
prescribed without increasing cyclosporin toxicity. Currently, a dos-
ing algorithm is under evaluation to determine cyclosporin dose
